The forgotten tale of Brazilian phage therapy
de Freitas Almeida, G. M., & Sundberg, L.-R. (2020). The forgotten tale of Brazilian phage therapy. The Lancet Infectious Diseases, 20(5), e90-e101. https://doi.org/10.1016/S1473-3099(20)30060-8
Julkaistu sarjassa
The Lancet Infectious DiseasesPäivämäärä
2020Tekijänoikeudet
© 2020 Elsevier Ltd. All rights reserved.
The use of bacteriophages to treat bacterial infections (known as phage therapy) is considered a possible solution to the antimicrobial resistance crisis. However, phage therapy is not a new concept. The discovery of phages in the early 20th century was closely tied to clinical practice, and phage therapy quickly spread around the world. The use of phage therapy in South America in the previous century is still shrouded in mystery and has been mentioned only briefly in recent scientific literature. Research on Brazilian reference collections of medical texts showed that Brazil was an important, but so far little-known, player of phage therapy, uncovering interesting priority claims and missing pieces of phage therapy history. Of note, there is the widespread use of phages against bacillary dysentery and staphylococcal infections, with José da Costa Cruz from the Oswaldo Cruz Institute (Rio de Janeiro, Brazil) as Brazil's leading expert and pioneer. This Historical Review about historical phage use in Brazil fills the gaps in our knowledge about the so-called golden years of phage therapy, providing information about successful experiences that can be useful against dangerous pathogens in our time.
...
Julkaisija
ElsevierISSN Hae Julkaisufoorumista
1473-3099Asiasanat
Julkaisu tutkimustietojärjestelmässä
https://converis.jyu.fi/converis/portal/detail/Publication/35102550
Metadata
Näytä kaikki kuvailutiedotKokoelmat
Rahoittaja(t)
Suomen AkatemiaRahoitusohjelmat(t)
Akatemiahanke, SALisätietoja rahoituksesta
This study was funded by the Academy of Finland (grant #314939) and by the Jane and Aatos Erkko Foundation. This work resulted from the BONUS FLAVOPHAGE project supported by BONUS (Art 185), funded jointly by the EU and Academy of FinlandLisenssi
Samankaltainen aineisto
Näytetään aineistoja, joilla on samankaltainen nimeke tai asiasanat.
-
Antibacterial efficiency of surface-immobilized Flavobacterium-infecting bacteriophage
Leppänen, Miika; Maasilta, Ilari; Sundberg, Lotta-Riina (American Chemical Society, 2019)Control of bacterial diseases by bacteriophages (phages) is gaining more interest due to increasing antibiotic resistance. This has led to technologies to attach phages on surfaces to form a biomaterial that can functionally ... -
Comparison of Delivery Methods in Phage Therapy against Flavobacterium columnare Infections in Rainbow Trout
Kunttu, Heidi M. T.; Runtuvuori-Salmela, Anniina; Middelboe, Mathias; Clark, Jason; Sundberg, Lotta-Riina (MDPI AG, 2021)Viruses of bacteria, bacteriophages, specifically infect their bacterial hosts with minimal effects on the surrounding microbiota. They have the potential to be used in the prevention and treatment of bacterial infections, ... -
Exploring phage-bacterium interactions : new ways to combat a fish pathogen
Laanto, Elina (University of Jyväskylä, 2014) -
Bacteriophage Adherence to Mucus Mediates Preventive Protection against Pathogenic Bacteria
Almeida, Gabriel M. F.; Laanto, Elina; Ashrafi, Roghaleh; Sundberg, Lotta-Riina (American Society for Microbiology, 2019)Metazoans were proposed to host bacteriophages on their mucosal surfaces in a symbiotic relationship, where phages provide an external immunity against bacterial infections and the metazoans provide phages a medium for ... -
Targeting antibiotic resistant bacteria with phage reduces bacterial density in an insect host
Mikonranta, Lauri; Buckling, Angus; Jalasvuori, Matti; Raymond, Ben (Royal Society Publishing, 2019)Phage therapy is attracting growing interest among clinicians as antibiotic resistance continues becoming harder to control. However, clinical trials and animal model studies on bacteriophage treatment are still scarce and ...
Ellei toisin mainittu, julkisesti saatavilla olevia JYX-metatietoja (poislukien tiivistelmät) saa vapaasti uudelleenkäyttää CC0-lisenssillä.